Leerink initiated coverage of CVS Health with an Outperform rating and $88 price target. CVS has built one of the broadest healthcare services enterprise in the market, and is still the largest retail pharmacy player, one of the two largest pharmacy benefit managers, and one of the largest managed care providers, the analyst tells investors in a research note. The firm sees a pathway towards rebooting core growth, which will come with the high-end cash flow generation CVS has always had.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- Grubhub offers items from CVS Pharmacy
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- CVS Health price target lowered to $83 from $84 at Wells Fargo
- CVS Health price target lowered to $92 from $100 at Morgan Stanley
- A New Cause for Concern: CVS Health Corp Adds a New Corporate Activity and Growth Risk